In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) closed the day trading at $7.54 up 4.14% from the previous closing price of $7.24. In other words, the price has increased by $4.14 from its previous closing price. On the day, 2.13 million shares were traded. ARQT stock price reached its highest trading level at $7.555 during the session, while it also had its lowest trading level at $6.9902.
Ratios:
For a better understanding of ARQT, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.61 and its Current Ratio is at 9.89. In the meantime, Its Debt-to-Equity ratio is 0.92 whereas as Long-Term Debt/Eq ratio is at 0.92.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Mizuho on January 03, 2024, Upgraded its rating to Buy and sets its target price to $8 from $4 previously.
On October 26, 2023, Mizuho Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $57 to $4.
Goldman Downgraded its Buy to Neutral on October 13, 2023, whereas the target price for the stock was revised from $32 to $6.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 04 ’24 when Welgus Howard G. sold 10,000 shares for $8.01 per share. The transaction valued at 80,092 led to the insider holds 170,200 shares of the business.
Burnett Patrick sold 23,000 shares of ARQT for $201,319 on May 30 ’24. The insider now owns 209,793 shares after completing the transaction at $8.75 per share. On May 29 ’24, another insider, Burnett Patrick, who serves as the insider of the company, sold 49,952 shares for $8.72 each. As a result, the insider received 435,387 and left with 209,793 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARQT now has a Market Capitalization of 872860544 and an Enterprise Value of 675735808. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.20 while its Price-to-Book (P/B) ratio in mrq is 3.87. Its current Enterprise Value per Revenue stands at 6.351 whereas that against EBITDA is -3.466.
Stock Price History:
Over the past 52 weeks, ARQT has reached a high of $13.17, while it has fallen to a 52-week low of $1.76. The 50-Day Moving Average of the stock is -17.84%, while the 200-Day Moving Average is calculated to be 18.98%.
Shares Statistics:
Over the past 3-months, ARQT traded about 3.25M shares per day on average, while over the past 10 days, ARQT traded about 2506560 shares per day. A total of 96.79M shares are outstanding, with a floating share count of 90.32M. Insiders hold about 21.98% of the company’s shares, while institutions hold 98.51% stake in the company. Shares short for ARQT as of 1715731200 were 22173654 with a Short Ratio of 6.83, compared to 1713139200 on 19662102. Therefore, it implies a Short% of Shares Outstanding of 22173654 and a Short% of Float of 23.76.
